Weight Change and Accumulation of Chronic Conditions in Women During Reproductive Years.

Obesity (Silver Spring)

Australian Women and Girls' Health Research Centre, School of Public Health, The University of Queensland, Herston, Queensland, Australia.

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: We examined the association between BMI change and risk of multimorbidity among women of reproductive age and estimated annual weight gain before and after diagnosis of chronic conditions.

Methods: Data were from 8895 women in the Australian Longitudinal Study on Women's Health who had no chronic conditions at baseline. BMI from Survey 1 (ages 18-23) and Survey 3 (ages 25-30) defined BMI change categories. Linear mixed models estimated annual weight gain from Survey 1 to Survey 9 (ages 43-49).

Results: Compared to stable normal BMI, stable obesity and increasing BMI were associated with a higher risk of incident multimorbidity (OR = 1.79 [95% CI: 1.11, 2.90] and 1.34 [1.10, 1.63]). Women who remained free of chronic conditions gained 0.50 kg (0.48, 0.52) annually. Women with one condition gained 0.54 kg (0.52, 0.56): 0.55 (0.53, 0.57) before and 0.54 (0.51, 0.57) after diagnosis. Those with multimorbidity gained 0.65 kg (0.63, 0.67): 0.75 kg (0.70, 0.80) before the first, 0.60 kg (0.56, 0.64) between the first and second, and 0.57 kg (0.53, 0.61) after the second condition.

Conclusions: Although weight gain declined after diagnosis, it remained higher than among women without conditions, underscoring the need for improved post-diagnosis weight management.

Download full-text PDF

Source
http://dx.doi.org/10.1002/oby.70023DOI Listing

Publication Analysis

Top Keywords

chronic conditions
12
weight gain
12
survey ages
12
women reproductive
8
bmi change
8
estimated annual
8
annual weight
8
women
6
weight
5
bmi
5

Similar Publications

Background: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) etiologies to study its underlying molecular heterogeneity.

Methods: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an eGFR of 25 to 75 mL/min/1.73m2 and a UACR of 200 to 5000 mg/g.

View Article and Find Full Text PDF

Epilepsy is a common chronic nervous system disease that threatens human health. However, the role of FOXC1 and its relations with pyroptosis have not been fully studied in epilepsy. Sprague-Dawley rats were obtained for constructing temporal lobe epilepsy (TLE) models.

View Article and Find Full Text PDF

Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which dysregulated interferon regulatory factor 5 (IRF5) may amplify pro-inflammatory pathways; prior genetic studies of IRF5 single-nucleotide variants (SNVs) in RA are inconsistent across populations and have not included mestizo Mexicans or evaluated rs59110799 in RA. We aimed to test whether four IRF5 SNVs (rs2004640G/T, rs2070197T/C, rs10954213G/A, rs59110799G/T) confer susceptibility to RA in women from Central Mexico. In a case-control study of 239 women with RA and 231 female controls (all self-identified Mexican-Mestizos, ≥3 generations), genotyping was performed by real-time PCR with TaqMan® probes; 80% of samples were duplicated (100% concordance) and control genotypes conformed to Hardy-Weinberg equilibrium.

View Article and Find Full Text PDF

Anti-inflammatory and immunomodulatory effect of purslane and turmeric in rheumatoid arthritis rat models.

Cell Mol Biol (Noisy-le-grand)

September 2025

Department of Chemistry, Faculty of Science and Health, Koya University, Koya, KOY45, Kurdistan Region, Iraq.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation. Given the side effects of conventional treatments, this study focuses on the anti-inflammatory effects of purslane (Portulaca oleracea) and turmeric (Curcuma longa). The research is driven by the growing demand for plant based-treatment for safer therapeutic options for RA management.

View Article and Find Full Text PDF